TY - JOUR T1 - A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human Cancer JF - Anticancer Research JO - Anticancer Res SP - 3373 LP - 3382 VL - 36 IS - 7 AU - PINELOPI SAMARA AU - MARGARITA SKOPELITI AU - MARINOS L. TSIATAS AU - SYLVIANNA GEORGAKI AU - CHARILAOS GOULOUMIS AU - WOLFGANG VOELTER AU - ATHANASSIOS-MELETIOS DIMOPOULOS AU - ARISTOTLE BAMIAS AU - OURANIA E. TSITSILONIS Y1 - 2016/07/01 UR - http://ar.iiarjournals.org/content/36/7/3373.abstract N2 - Background/Aim: Peripheral blood mononuclear cells (PBMCs) activated with immobilized monoclonal antibody against cluster of differentiation 3 (CD3) secrete cytokines in their culture supernatant (termed ACD3S). We examined the antitumor efficacy of ACD3S-activated NK-92 cells in vitro and in vivo. Materials and Methods: Interleukin (IL) 2-depleted NK-92 cells were reactivated with ACD3S, analyzed for their phenotype and tested for cytotoxicity, and perforin and interferon γ (IFNγ) production. Severe combined immunodeficient (SCID) mice xenografted with human melanoma and breast cancer cells were treated with ACD3S-activated NK-92 cells and tumor growth was monitored. Results: Brief activation of IL2-depleted NK-92 cells with ACD3S fully restored their in vitro cytotoxicity towards tumor cells. ACD3S-activated NK-92 cells were phenotypically similar to standard NK-92 cells, but exhibited prolonged cytotoxicity and produced higher levels of IFNγ. When adoptively transferred to tumor-bearing SCID mice, these cells retarded the growth of melanoma and breast tumors. Conclusion: Stimulation of NK-92 cells with ACD3S may be useful in clinical cancer therapy, as an alternative method for ex vivo natural killer cell activation. ER -